What is Affimed?
Founded in 2000 and headquartered in Heidelberg, Baden-Wuerttemberg, Affimed is dedicated to advancing immuno-oncology treatments. The company's proprietary platform is designed to identify and develop therapies targeting specific patient populations, aiming to revolutionize cancer care. This focus positions Affimed at the forefront of precision medicine within the competitive oncology landscape.
How much funding has Affimed raised?
Affimed has raised a total of $86.4M across 2 funding rounds:
Stock Offering
$56M
Debt
$30.4M
Stock Issuance/Offering (2014): $56M, investors not publicly disclosed
Debt (2021): $30.4M led by Silicon Valley Bank
Key Investors in Affimed
Silicon Valley Bank
Silicon Valley Bank is a financial institution that provides commercial and private banking services, along with asset management and investment services. Their involvement suggests a focus on supporting companies with significant growth potential in the technology and life sciences sectors.
What's next for Affimed?
The recent major strategic investment signals a pivotal moment for Affimed, likely enabling accelerated development of its clinical pipeline and expansion of its research initiatives. This infusion of capital is expected to support further clinical trials, potential regulatory submissions, and the scaling of its operational capabilities. Affimed's trajectory suggests a strong emphasis on translating its innovative platform into tangible therapeutic solutions for patients battling cancer.
See full Affimed company page
